

<b>Meeting: Primary Care Commissioning Committee</b>			
<b>Meeting Date</b>	28 March 2018	<b>Action</b>	Receive
<b>Item No.</b>	5	<b>Confidential</b>	No
<b>Title</b>	Bury Pharmaceutical Needs Assessment 2018-2021		
<b>Presented By</b>	Stephen Woods – Greater Manchester Shared Services		
<b>Author</b>	Stephen Woods – Greater Manchester Shared Services		
<b>Clinical Lead</b>	-		

### **Executive Summary**

The Pharmacy Needs Assessment (PNA) was last completed in 2015 – the results of which are published on the JSNA. It is a legal document which details services which would be desirable and necessary in a locality based on the local health needs and population demographics. There is a requirement for the Bury PNA to be refreshed by 31<sup>st</sup> March 2018.

The Health and Social Care Act 2012 transferred the responsibility for developing and updating the PNAs to the LA Health and Wellbeing Boards (HWBs). The NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 set out the legislative basis for developing and updating PNAs and can be found at: <http://www.dh.gov.uk/health/2013/02/pharmaceutical-services-regulations/>.

Bury Council and CCG, along with the other localities within Greater Manchester, have commissioned Greater Manchester Shared Services (GMSS) to undertake the development of the revised PNA. The GMSS met a steering group for this locally, which included the Council, CCG, Healthwatch and LPC to discuss the process.

A public survey was launched on the 9<sup>th</sup> June, through an online questionnaire with paper made available at local libraries and pharmacies. This was to understand the local view on access to and use of pharmacies. At the same time a survey took place of local pharmacies on their provision, and an analysis of existing data on local demographics.

The findings of these surveys have and data analysis have formed the basis of the draft PNA, taken to the September Health and Wellbeing board. Subsequently following approval the PNA has been sent to all mandatory contacts, for the mandatory 60 day consultation and the comments have been collated and reflected in this final version of the PNA as agreed by the Health and Wellbeing board on 14<sup>th</sup> February 2018.

The final PNA being brought to PCCC outlines a background to the duties and purposes concerning a PNA; how the assessment has been undertaken; provision of pharmaceutical services; how pharmaceutical services can help support a healthier population; and whether there are any gaps in current provision.

The PNA concluded no gaps in pharmaceutical services had been established.

Recommendations
<p>It is recommended that the Primary Care Commissioning Committee:</p> <ul style="list-style-type: none"> <li>Receive the report for information following approval at the Health and Wellbeing Board on the 14<sup>th</sup> February 2018.</li> </ul>

Links to CCG Strategic Objectives	
To empower patients so that they want to, and do, take responsibility for their own healthcare. This includes prevention, self-care and navigation of the system.	<input checked="" type="checkbox"/>
To deliver system wide transformation in priority areas through innovation	<input checked="" type="checkbox"/>
To develop Primary Care to become excellent and high performing commissioners	<input checked="" type="checkbox"/>
To work with the Local Authority to establish a single commissioning organisation	<input checked="" type="checkbox"/>
To maintain and further develop robust and effective working relationships with all stakeholders and partners to drive integrated commissioning.	<input checked="" type="checkbox"/>
To deliver long term financial sustainability in partnership with all stakeholders through innovative investment which will benefit the whole Bury economy.	<input checked="" type="checkbox"/>
To develop the Locality Care Organisation to a level of maturity such that it can consistently deliver high quality services in line with Commissioner's intentions.	<input checked="" type="checkbox"/>
Supports NHS Bury CCG Governance arrangements	<input checked="" type="checkbox"/>
Does this report seek to address any of the risks included on the Governing Body Assurance Framework? If yes, state which risk below:	
GBAF [ <i>Insert Risk Number and Detail Here</i> ]	

Implications						
Are there any quality, safeguarding or patient experience implications?	Yes	<input type="checkbox"/>	No	<input checked="" type="checkbox"/>	N/A	<input type="checkbox"/>
<i>If you have ticked yes provide details here. Delete this text if you have ticked No or N/A</i>						
Are there any conflicts of interest arising from the proposal or decision being requested?	Yes	<input type="checkbox"/>	No	<input checked="" type="checkbox"/>	N/A	<input type="checkbox"/>
<i>If you have ticked yes provide details here. Delete this text if you have ticked No or N/A</i>						
Are there any financial Implications?	Yes	<input type="checkbox"/>	No	<input checked="" type="checkbox"/>	N/A	<input type="checkbox"/>
<i>If you have ticked yes provide details here. Delete this text if you have ticked No or N/A</i>						
Has a Equality, Privacy or Quality Impact Assessment been completed?	Yes	<input checked="" type="checkbox"/>	No	<input type="checkbox"/>	N/A	<input type="checkbox"/>
Is a Equality, Privacy or Quality Impact Assessment required?	Yes	<input checked="" type="checkbox"/>	No	<input type="checkbox"/>	N/A	<input type="checkbox"/>
Are there any associated risks?	Yes	<input type="checkbox"/>	No	<input checked="" type="checkbox"/>	N/A	<input type="checkbox"/>
Are the risks on the CCG's risk register?	Yes	<input type="checkbox"/>	No	<input type="checkbox"/>	N/A	<input checked="" type="checkbox"/>

*If you have ticked yes provide details here. If you are unsure seek advice from Lynne Byers about the risk register.*



Equality Analysis  
Feb 2018.docx

<b>Governance and Reporting</b>		
<b>Meeting</b>	<b>Date</b>	<b>Outcome</b>
Health and Wellbeing Board	14/02/2018	Full board Approval

## **Pharmaceutical Needs Assessment 2018-2021**

### **1. Introduction**

- 1.1. From 1st April 2013, Bury Health and Wellbeing Board (HWB) has had a statutory responsibility to publish and keep up-to-date a statement of the needs for pharmaceutical services for the population in its area, referred to as a 'pharmaceutical needs assessment' (PNA).
- 1.2. The PNA aims to identify whether current pharmaceutical service provision meets the needs of the population. The PNA considers whether there are any gaps to service delivery.
- 1.3. The PNA may be used to inform commissioners such as clinical commissioning groups (CCG) and local authorities (LA), of the current provision of pharmaceutical services and where there are any gaps in relation to the local health priorities. Where such gaps are not met by NHS England, these gaps may then be considered by those organisations.
- 1.4. The PNA will be used by NHS England in its determination as to whether to approve applications to join the pharmaceutical list under The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. The relevant NHS England area team (AT) will then review the application and decide if the application meets the criteria for approval, as set out in the Regulations. When making the decision NHS England is required to refer to the local PNA.

### **2. Background**

- 2.1. The Pharmacy Needs Assessment (PNA) was last completed in 2015 – the results of which are published on the JSNA. It is a legal document which details services which would be desirable and necessary in a locality based on the local health needs and population demographics. There is a requirement for the Bury PNA to be refreshed by 31st March 2018.
- 2.2. Bury Council and CCG, along with the other localities within Greater Manchester, have commissioned Greater Manchester Shared Services (GMSS) to undertake the development of the revised PNA.

### **3. Bury Pharmaceutical Needs Assessment 2018-2021**

- 3.1 The Bury Pharmaceutical Needs Assessment outlines a background to the duties and purposes concerning a PNA; how the assessment has been undertaken; provision of pharmaceutical services; how pharmaceutical services can help support a healthier population; and whether there are any gaps in current provision.
- 3.2 The PNA concluded no gaps in pharmaceutical services had been established.

### **4 Associated Risks**

- 4.1 Brought for information and planning only. Risks are under the statutory function of Bury's Health and Wellbeing board.

## **5 Recommendations**

5.1 The PNA concluded no gaps in pharmaceutical services had been established.

5.2 The PNA has been brought to PCCC for information and to inform commissioning.

## **6 Actions Required**

- 6.1 The Primary Care Commissioning Committee is required to:
- Receive (information)

### **Michelle Foxcroft**

Intelligence Lead, Communities and wellbeing, Bury Council

m.foxcroft@bury.gov.uk

March 2018